The fact that TEVA has decided to hire a former senior level FDA Scientist as their US regulatory affairs VP suggests that they are unhappy with the progress on their reviews at the FDA.
That’s a reasonable inference, FL. However, when it comes to Lovenox, even a first-rate regulatory-affairs executive cannot simply wave a wand to make a deficient drug compliant.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”